News for Aerovate Therapeutics, Inc. (AVTE)

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations o

PR NewswireNEW YORK, Feb. 24, 2025 NEW YORK, Feb. 24, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following co

NEW YORK, Feb. 17, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations o

NEW YORK, Jan. 26, 2025 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations o

PR NewswireNEW YORK, Jan. 24, 2025 NEW YORK, Jan. 24, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following co

Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Aerovate Therapeutics, Inc. (NASDAQ: AVTE) and Jade Biosciences is fair t

PR NewswireNEW YORK, Dec. 23, 2024 NEW YORK, Dec. 23, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following co

NEW YORK, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations o

NEW YORK, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations o

PR NewswireNEW YORK, Nov. 27, 2024 NEW YORK, Nov. 27, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following co

Aerovate Therapeutics (AVTE) stock gains as company agreed to merge with Jade Biosciences in all-stock deal. Read more here.

Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement...

AVTE stock results show that Aerovate Therapeutics missed analyst estimates for earnings per share the second quarter of 2024.

Loading... Loading... Shares of Ovid Therapeutics Inc OVID dipped 65.7% to $1.1285 after Takeda’s Skyline study in Dravet syndrome missed its primary endpoin...

Aerovate Therapeutics Appoints Habib Dable To Its Board

/PRNewswire/ -- The "Global Pulmonary Arterial Hypertension Market: Analysis By Drug Class, By Type, By Route of Administration, By Distribution Channel, By...

U.S. stocks traded higher this morning, with the Dow Jones gaining over 600 points on Tuesday

Gainers Everspin Technologies, Inc. (NASDAQ:MRAM) shares surged 63.2% to close at $10.74 on Friday after the company reported better-than-expec...